anonymous
Guest
anonymous
Guest
So you may know (maybe you do not know) every company has multiple contingency plans laid out for different scenarios. I had the opportunity to see what the company has planned for 2020/21
Januvia will lose its patent in 2022. Promotion will cease in 2020/21 time frame. The projections are that current products will NOT fill the void and this plan laid out the demise of the chronic care team and current products would be sold. Merck would invest its resources in other more profitable business units.
Obviously if these products accelerated or other products were acquired things might change. However in the absence of such events, people should prepare for major changes in the future.
Januvia will lose its patent in 2022. Promotion will cease in 2020/21 time frame. The projections are that current products will NOT fill the void and this plan laid out the demise of the chronic care team and current products would be sold. Merck would invest its resources in other more profitable business units.
Obviously if these products accelerated or other products were acquired things might change. However in the absence of such events, people should prepare for major changes in the future.